Floatz logo

Dupilumab

Neoadjuvant Therapy

Centre hospitalier de l'Université de Montréal (CHUM)monoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Neoadjuvant Therapy cohort.

Asset / SponsorPhaseRating
Tislelizumab
Seventh Medical Center of PLA General Hospital
Phase 4BB
rc48-adc
First Affiliated Hospital of Guangxi Medical University
Phase 4BB
S-1
Tao Zhang
Phase 4B
FLUOROURACILUM
Azienda Unita Sanitaria Locale di Piacenza
Phase 4B
Capecitabine
Tao Zhang
Phase 3B

View all 50 →

Same molecule, other indications

Dupilumab is also rated in:

atopic eczemaDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
46 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →